Maxygen and Aventis sign vaccine pact
Maxygen and Aventis Pasteur have signed a three-year agreement todevelop improved vaccines for a specific undisclosed target, using the former's MolecularBreeding technologies. Maxygen claims that the latter "are ideally suited to improve vaccine products in key ways," including improving immunogenicity, purity and manufacturability.
Under the terms of the agreement, Maxygen will receive undisclosed license fees, full R&D funding, minimum annual royalties and potential milestone and royalty payments on product sales, while Aventis Pasteur will receive exclusive worldwide rights to commercialize the vaccines developed in the collaboration.
Maxygen already has deals in place with a number of leading companies, including InterMune, Lundbeck, Pfizer and DSM. It currently has a pipeline of over 40 potential products, with 10 in development, and has a total of 19 strategic alliances.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze